PALO ALTO, Calif., April 30, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory, President and CEO, will participate and present a corporate update at the ChinaBio® Partnering Forum 2019 on May 8 in Shanghai, China.
Eiger will host one-on-one meetings at the ChinaBio® Partnering Forum.
Eiger is a late stage biopharmaceutical company focused on the development and commercialization of a pipeline of first-in-class, well-characterized drugs for serious, rare and ultra-rare diseases for patients with high unmet medical needs and for which no approved therapies exist. We innovate by developing well-characterized drugs in newly identified or novel targets in rare diseases. Our mission is to systematically reduce the time and cost of the drug development process to more rapidly deliver important medicines to patients.
The company's lead program is in Phase 3, developing lonafarnib, a first-in-class prenylation inhibitor for the treatment of Hepatitis Delta Virus (HDV) infection. The company is rapidly advancing peginterferon lambda, a first-in-class interferon, toward registration for the treatment of HDV. Eiger is preparing an NDA and MAA for lonafarnib to treat Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and Progeroid Laminopathies with plans to file in 2019. For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.
Investors: Ingrid Choong, PhD
View original content to download multimedia:http://www.prnewswire.com/news-releases/eiger-to-present-at-chinabio-partnering-forum-2019-300840417.html
SOURCE Eiger BioPharmaceuticals, Inc.